Gland Pharma Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Net profit of Gland Pharma rose 12.32% to Rs 183.68 crore in the quarter ended September 2025 as against Rs 163.53 crore during the previous quarter ended September 2024. Sales rose 5.77% to Rs 1486.88 crore in the quarter ended September 2025 as against Rs 1405.83 crore during the previous quarter ended September 2024.

Powered by Capital Market - Live News

Gland Pharma will hold a meeting of the Board of Directors of the Company on 3 November 2025.

Powered by Capital Market - Live News

Gland Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 1915.3, up 1.55% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.43% on the day, quoting at 24628.25. The Sensex is at 80338.6, down 0.47%. Gland Pharma Ltd has dropped around 2.16% in last one month.

Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has dropped around 1.55% in last one month and is currently quoting at 21915.4, down 0.26% on the day. The volume in the stock stood at 1.1 lakh shares today, compared to the daily average of 2.57 lakh shares in last one month.

The PE of the stock is 27.37 based on TTM earnings ending June 25.

Powered by Capital Market - Live News

The company also received tentative approval for the (0.2 Units/mL) RTU vials of the same formulation.

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), VASOSTRICT Injection (0.4 Units/mL) and (0.2 Units/mL) of PH Health.

This product is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.

According to IQVIA, the product recorded U.S. sales of approximately USD 45 million for the twelve months ending June 2025.

Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India.

The company?s consolidated net profit surged 49.88% to Rs 215.48 crore in Q1 FY26 as against Rs 143.76 crore posted in Q1 FY25. Revenue from operations increased by 7.41% YoY to Rs 1,505.62 crore for the quarter ended 30 June 2025.

The counter shed 0.05% to Rs 1,941 on the BSE.

Powered by Capital Market - Live News